JP2024504164A5 - - Google Patents
Info
- Publication number
- JP2024504164A5 JP2024504164A5 JP2023544489A JP2023544489A JP2024504164A5 JP 2024504164 A5 JP2024504164 A5 JP 2024504164A5 JP 2023544489 A JP2023544489 A JP 2023544489A JP 2023544489 A JP2023544489 A JP 2023544489A JP 2024504164 A5 JP2024504164 A5 JP 2024504164A5
- Authority
- JP
- Japan
- Prior art keywords
- icd
- codon
- optimized
- tmd
- zeta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141016P | 2021-01-25 | 2021-01-25 | |
| US63/141,016 | 2021-01-25 | ||
| US202163270414P | 2021-10-21 | 2021-10-21 | |
| US63/270,414 | 2021-10-21 | ||
| PCT/US2022/013458 WO2022159791A1 (en) | 2021-01-25 | 2022-01-24 | Cd27-extracellular domain car to target cd70-positive tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504164A JP2024504164A (ja) | 2024-01-30 |
| JP2024504164A5 true JP2024504164A5 (enExample) | 2025-01-29 |
Family
ID=82549264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544489A Pending JP2024504164A (ja) | 2021-01-25 | 2022-01-24 | Ｃｄ７０陽性腫瘍を標的とするｃｄ２７－細胞外ドメインｃａｒ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250281612A1 (enExample) |
| EP (1) | EP4281483A4 (enExample) |
| JP (1) | JP2024504164A (enExample) |
| KR (1) | KR20230136184A (enExample) |
| AU (1) | AU2022210461A1 (enExample) |
| CA (1) | CA3209110A1 (enExample) |
| IL (1) | IL304635A (enExample) |
| MX (1) | MX2023008676A (enExample) |
| WO (1) | WO2022159791A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251290A1 (en) * | 2023-06-09 | 2024-12-12 | Suzhou Cure Genetics Biosciences Co., Limited | Engineered immune cells and uses thereof |
| WO2025029351A1 (en) * | 2023-07-28 | 2025-02-06 | Adicet Therapeutics, Inc. | Multispecific chimeric antigen receptor (car)-t cells directed to cd70 and methods of use thereof |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013004792A (es) * | 2010-10-27 | 2013-08-27 | Baylor College Medicine | Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas. |
| EP3230310B1 (en) * | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
| WO2019119036A1 (en) * | 2017-12-19 | 2019-06-27 | Benitec Biopharma Limited | Cd70 deficient cells, and methods and reagents for producing same |
| CN109880802B (zh) * | 2018-11-30 | 2022-12-13 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
| WO2020259541A1 (zh) * | 2019-06-25 | 2020-12-30 | 浙江康佰裕生物科技有限公司 | 一种用于肿瘤治疗的嵌合抗原受体t淋巴细胞及其制备方法与应用 |
| WO2022129216A1 (en) * | 2020-12-15 | 2022-06-23 | Universiteit Antwerpen | Cell-based therapeutics targeting cd70 |
-
2022
- 2022-01-24 WO PCT/US2022/013458 patent/WO2022159791A1/en not_active Ceased
- 2022-01-24 CA CA3209110A patent/CA3209110A1/en active Pending
- 2022-01-24 US US18/261,414 patent/US20250281612A1/en active Pending
- 2022-01-24 AU AU2022210461A patent/AU2022210461A1/en active Pending
- 2022-01-24 EP EP22743308.3A patent/EP4281483A4/en active Pending
- 2022-01-24 MX MX2023008676A patent/MX2023008676A/es unknown
- 2022-01-24 JP JP2023544489A patent/JP2024504164A/ja active Pending
- 2022-01-24 KR KR1020237028916A patent/KR20230136184A/ko active Pending
-
2023
- 2023-07-20 IL IL304635A patent/IL304635A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404492B2 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| US12404338B2 (en) | Anti CD30 chimeric antigen receptor and its use | |
| JP7264954B2 (ja) | Ｈｅｒ２を標的とするキメラ抗原受容体 | |
| JP2024504164A5 (enExample) | ||
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| JP2023509766A5 (enExample) | ||
| JP2024519515A5 (enExample) | ||
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| JP2024527559A5 (enExample) | ||
| JP7467414B2 (ja) | 改良したｔ細胞治療方法 | |
| JP2024525609A5 (enExample) | ||
| JP2024521185A5 (enExample) | ||
| JP2022548902A5 (enExample) | ||
| JP2024526237A5 (enExample) | ||
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| Schirrmann et al. | Emerging Therapeutic Concepts III: Chimeric Immunoglobulin T Cell Receptors, T‐Bodies | |
| EP4061385A1 (en) | A method for redesign and expansion of nk92 cells for use in immunotherapy | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| NZ742136A (en) | Improved methods for manufacturing adoptive cell therapies | |
| NZ742136B2 (en) | Improved methods for manufacturing adoptive cell therapies | |
| HK1248273A1 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| HK1248273B (en) | Methods for enhancing efficacy of therapeutic immune cells |